key: cord-0882373-kgyiz0se
authors: Modi, C.; Dragun, A.E.; Henson, C.F.; Jain, S.; Ahlawat, S.; Eastwick, G.; Kubicek, G.J.; Mezera, M.; Mulvihill, D.J.; Perri, J.; Juneja, B.; Khullar, K.; Ennis, R.D.; Haffty, B.G.
title: A Statewide Multi-institutional Study of Asymptomatic Pre-Treatment Testing of Radiation Therapy Patients for SARS-CoV-2 in a High-Incidence Region of the United States
date: 2021-04-20
journal: Adv Radiat Oncol
DOI: 10.1016/j.adro.2021.100704
sha: 0393b1b6d9f586f28fdb0ece348591b56e0f1877
doc_id: 882373
cord_uid: kgyiz0se

PURPOSE/OBJECTIVE(S): To establish the prevalence of SARS-CoV-2 in asymptomatic patients scheduled to receive radiation therapy and its impact on management decisions. MATERIALS/METHODS: Between April 2020 and July 2020, patients without influenza-like-illness (ILI) symptoms at four radiation oncology departments (2 academic university hospitals and 2 community hospitals) underwent polymerase chain reaction (PCR) testing for SARS-CoV-2 prior to the initiation of treatment. Patients were tested either prior to radiotherapy simulation or after simulation but prior to treatment initiation. Patients tested for indications of ILI symptoms were excluded from this analysis. Management of SARS-CoV-2-positive patients was individualized based on disease site and acuity. RESULTS: Over a three-month period, a total of 385 tests were performed in 336 asymptomatic patients either prior to simulation (n=75), post-simulation, prior to treatment (n=230), or on-treatment (n=49). A total of 5 patients tested positive for SARS-CoV-2, for a pre-treatment prevalence of 1.3% (2.6% in North/Central NJ and 0.4% in Southern NJ/Southeast PA). The median age of positive patients was 58 years (range: 38-78 years). All positive patients were white and were relatively equally distributed with regard to gender (2 male, 3 female) and ethnicity (2 Hispanic and 3 non-Hispanic). The median Charlson comorbidity score among positive patients was 5. All 5 patients were treated for different primary tumor sites, the large majority had advanced disease (80%), and all were treated for curative intent. The majority of positive patients were being treated with either sequential or concurrent immunosuppressive systemic therapy (80%). Initiation of treatment was delayed for 14 days with the addition of re-testing for 4 patients, while one patient was treated without delay but with additional infectious-disease precautions. CONCLUSION: Broad-based pre-treatment asymptomatic testing of radiation oncology patients for SARS-CoV-2 is of limited value, even in a high-incidence region. Future strategies may include focused risk-stratified asymptomatic testing.

In our study, we examine the prevalence of SARS-CoV-2 in asymptomatic patients scheduled to receive radiation therapy. In a sample of 336 asymptomatic patients, we found a low pretreatment prevalence of 1.3%, indicating that broad-based pre-treatment asymptomatic testing of radiation oncology patients for SARS-CoV-2 is of limited value. Future strategies may include focused risk-stratified asymptomatic testing.

Purpose/Objective(s): To establish the prevalence of SARS-CoV-2 in asymptomatic patients scheduled to receive radiation therapy and its impact on management decisions. Materials/Methods: Between April 2020 and July 2020, patients without influenza-like-illness (ILI) symptoms at four radiation oncology departments (2 academic university hospitals and 2 community hospitals) underwent polymerase chain reaction (PCR) testing for SARS-CoV-2 prior to the initiation of treatment. Patients were tested either prior to radiotherapy simulation or after simulation but prior to treatment initiation. Patients tested for indications of ILI symptoms were excluded from this analysis.

Management of SARS-CoV-2-positive patients was individualized based on disease site and acuity.

Results: Over a three-month period, a total of 385 tests were performed in 336 asymptomatic patients either prior to simulation (n=75), post-simulation, prior to treatment (n=230), or on-treatment (n=49). A total of 5 patients tested positive for SARS-CoV-2, for a pre-treatment prevalence of 1.3% (2.6% in North/Central NJ and 0.4% in Southern NJ/Southeast PA). The median age of positive patients was 58 years (range: 38-78 years). All positive patients were white and were relatively equally distributed with regard to gender (2 male, 3 female) and ethnicity (2 Hispanic and 3 non-Hispanic). The median Charlson comorbidity score among positive patients was 5. All 5 patients were treated for different primary tumor sites, the large majority had advanced disease (80%), and all were treated for curative intent. The majority of positive patients were being treated with either sequential or concurrent immunosuppressive systemic therapy (80%). Initiation of treatment was delayed for 14 days with the addition of re-testing for 4 patients, while one patient was treated without delay but with additional infectious-disease precautions.

Conclusion: Broad-based pre-treatment asymptomatic testing of radiation oncology patients for SARS-CoV-2 is of limited value, even in a high-incidence region. Future strategies may include focused riskstratified asymptomatic testing.

In Spring 2020, the rapid spread of COVID-19 caused widespread concern throughout the country. At the peak of the pandemic, New Jersey had the second-highest incidence of cases and death per capita due to COVID-19, and a state of emergency was declared in March 2020. While testing in early April was limited to symptomatic patients only , the positivity rate was over 50% and by the middle of the month, the COVID-19 deaths peaked at 412 deaths on April 13-over 20% of all COVID-19 related deaths in the country. 1

Though cases and death rates throughout the United States were rising, there were no clear guidelines in place for testing asymptomatic patients with SARS-COV-2. Early data during the pandemic revealed that immunocompromised patients were a high-risk cohort and that cancer patients were particularly vulnerable to COVID-19, making early detection invaluable for their oncologic care. 2 However, even amongst academic societies in cancer care, there was no clear consensus on testing.

American Society of Radiation Oncology (ASTRO) began issuing clinical guidance in late March, with sitespecific guidelines beginning in April. 3 Yale School of Medicine had also put forth their strategy for triaging patients, delaying treatment, using PPE, and limiting exposure to patients with the use of telehealth. 4 Notably, however, oncologic societies did not comment on testing for asymptomatic patients.

This study aims to better clarify the utility of asymptomatic SARS-COV-2 testing in the radiation oncology setting. The logic underpinning an asymptomatic testing strategy is that it would not only prevent adverse outcomes among potentially immunosuppressed cancer patients , but also mitigate the risk of asymptomatic transmission to other patients and staff who share the linear accelerator (LINAC) room environment. The limitations of such testing was also understood, in that it provides only a "snapshot" of infection status at a moment in time and is not protective or predictive of future infection. Therefore, our testing also did not take into account exposures after first day of treatment. This study represents an unprecedented inter-institutional collaboration, deployed in record time, to address this crucial clinical question.

Implementation of asymptomatic testing strategy.

In mid-April 2020, during the peak of symptomatic daily confirmed case incidence of SARS-CoV-2 (Covid-19), the statewide cancer program collaboration group (XXXXXX) was formed to share best practices for the safe treatment of cancer patients in the pandemic setting. A radiation-oncology subspecialty division of this group met weekly to discuss personal protective equipment use (PPE), sanitization practices, screening of patients and preventative measures, as well as the treatment of patients with confirmed Covid-19. During this period (extending to June 1, 2020), state governors' executive orders in the region (NJ, NY, PA) restricted so-called "elective" surgeries. At the same time, increased testing capabilities were deployed within the region as a component of the US federal response.

The US Centers for Disease Control (CDC) was discouraging the practice of asymptomatic testing among the general public; however, there was increasing interest in testing asymptomatic cancer patients prior to the initiation of treatment. Routine pre-treatment testing was first deployed to inpatient (and, soon after, outpatient) chemotherapy patients with the rationale of identifying early infection in a potentially immunosuppressed population. With increased testing capacity, attention turned to outpatient radiation oncology, where the main rationale for pre-treatment asymptomatic testing was preventing occult transmission to therapy staff and other patients who all share the same LINAC space. Although limitations of one-time testing were understood, by late-April 2020, most institutions in the XXXXXX had implemented an asymptomatic testing strategy to complement other widely-adopted preventative measures (symptom and exposure questionnaires, limiting visits, social distancing, and PPE).

This study represents a retrospective review of prospectively-collected databases of asymptomatic patients tested for Covid-19 at four institutions participating in the XXXXXX: two academic medical centers ("Anonymized for Review") and two community hospitals ("Anonymized for Review").

These institutions matched their Covid-19 testing databases to patient information including demographic, disease-site, medical cormorbidity, and treatment details. Databases were then deidentified, and inter-institutional contracting was executed to allow sharing of limited data sets and compilation at the coordinating institution ("Anonymized for Review") under an expedited retrospective IRB protocol (#20-437).

Patients who commenced outpatient radiation therapy during a three-month period (April 27, 2020-July 31, 2020) and who had no symptoms of influenza-like-illness (ILI) and who underwent polymerase chain reaction (PCR) testing for SARS-CoV-2 prior to the initiation of treatment were eligible for inclusion in this analysis. Patients who were tested for the indication of ILI symptoms, inpatients, and those who refused testing were excluded. Testing strategy varied among institutions and included testing of all patients, or selected patients based on risk (nursing home patients, those undergoing chemotherapy, inability to wear a mask). Patients were tested prior to simulation, after simulation but prior to first treatment, and/or at selected intervals on-treatment, according to varying institutional capabilities. Patients who were found to be asymptomatic positive for Covid-19 were managed according to best practices, considering disease factors and evolving CDC guidelines.

Statistical Analysis.

The coordinating institution carried out statistical analysis of the limited data sets using R Core Team software (Vienna, Austria. http://www.R-project.org/). Two-tailed Fisher's exact test was used to assess whether the dependence of positive pre-treatment Covid-19 results on an explanatory variable was statistically significant (α < 0.05). To analyze combination of variables, two-tailed Fisher's Exact test was used, but, for the contingency table, the independent variable was considered positive if both explanatory variables were positive. If either or both were negative, the independent variable was considered negative. This allowed analyzing multiple explanatory variables in combination to assess if having both increased the proportions of positive pre-treatment Covid-19 results. The null hypothesis was that the relative proportions of the positive pre-treatment Covid-19 results were independent of the explanatory variable.

During a three-month period, a total of 385 PCR nasal swab tests for SARS CoV2 were performed in 336 asymptomatic radiation oncology patients. According to CDC, the 7-day average of daily confirmed cases in our region ranged from 3,197 in late-April to 295 in late-July, 2020 (Figure 1) . The percent positivity rate ranged from 43% to under 2%. 1 The demographics and medical comorbidities of the 336 analyzed patients are shown in Table 1 . A majority of patients were ≥ 45 years (89.9%), approximately 20% were African American, 15% were Hispanic, and a majority (53.3%) had a comorbidity score > 5.

Disease site, stage and treatment information are presented in Table 2 . The top three diseasesites for patients undergoing treatment were breast (27.1%), thoracic (18.5%), and genitourinary (12.8%) malignancies. In terms of stage, the overwhelming majority of patients were treated for locallyadvanced or metastatic disease (74/4%). Radiation therapy was largely external-beam treatment without brachytherapy (93.2%), and a majority of patients were undergoing some form of sequential and/or concurrent chemotherapy (56.8%).

The testing strategy for the 385 tests that were performed, as well as the testing results are shown in Table 3 . Approximately 70% of patients tested were undergoing radiation therapy alone with no other patient risk factors. The overwhelming majority of patients were tested after simulation but prior to first treatment (67.8%), and most tests results were available within 24-72 hours (78.4%). A total of 5 positive tests were observed for a pre-treatment asymptomatic prevalence rate of 1.3%. The details and management strategy of the 5 positive patents are shown in Table 4 . Initiation of treatment was delayed for 14 days with the addition of re-testing for 4 patients, while one patient with locallyadvanced head and neck cancer was treated without delay but with additional infectious-disease precautions (therapists in full PPE, treatment at the end of the day with a terminal room clean).

Statistical analysis using univariate and multivariate Fisher's Exact Test to determine factors predictive of a positive test are presented in Table 5 . Regional location (North/Central NJ, p=0.024) as well as Hispanic ethnicity (p=0.036) were found to be statistically significant on univariate analysis. On multivariate analysis, patients treated with concurrent and/or sequential chemotherapy who were Hispanic (p=0.005) or who had locally advanced disease (p=0.019) were at highest likelihood for a positive asymptomatic test.

Asymptomatic COVID-19 infections have been reported since the beginning of pandemic, with the CDC estimating 40% of infections to be asymptomatic, and a latency time of six days 5 . Several prior studies have found variable asymptomatic rates ranging from 20% to 75% of cases, thus suggesting that isolation of symptomatic patients as the sole strategy of controlling the pandemic is likely to be ineffective 6, 7 . Specifically, Chang et al demonstrated that the probability of control decreases with an increase in asymptomatic transmission, a decrease in proper contact tracing, and a longer time from infection to isolation. 8 While masks have been shown to mitigate transmission among both symptomatic and asymptomatic individuals, prior studies have indicated the need to impose stricter contact tracing and testing regardless of symptoms, especially given that the spread of COVID-19 is largely driven by asymptomatic cases. 9 Data on testing in asymptomatic cancer patients remains scarce and early studies have found the asymptomatic rate to be uncertain and highly variable. An early study from Germany tested 139 asymptomatic cancer patients before beginning radiation treatment from April 17 to May 8th, and found one positive patient, translating into a COVID prevalence rate of 0.72% 10 . In another study by a hospital in Dubai, 85 asymptomatic cancer patients were tested between March 13 th and April 4 th . Seven patients (8.24%) of those tested were positive for COVID-19. All of them subsequently developed symptomatic disease 11 . In a study by Lee et al from the UK, 1,226 patients undergoing chemotherapy from April 3 to June 22th were tested, with an asymptomatic rate of 0.6% 12 .

Other than our initial results published in abstract form 13 , to our knowledge there have been no published results of asymptomatic testing in radiation oncology patients in the United States. While asymptomatic cases contribute to a significant amount of transmission, our study indicates that blanket asymptomatic testing may not be the optimal strategy in reducing this transmission in this population.

Rather, a more targeted approach based on high-risk factors may provide more value. There are several important factors that are associated with an increased risk for transmission and adverse outcomes. For example, minority populations have been shown to be disproportionately affected by the pandemic with a higher rate of cases, hospitalizations, and deaths. 14-16 . In a study by Goyal et al, minority children were found to have higher rates of infection, while children with the highest median family income had lower rates of infection. 15 Moreover, Kim et al showed that non-English speakers were not only less likely to have completed testing, but also had a 4.6 fold higher proportion of positive cases compared to English speakers . 16 Finally, Muñoz-Price et al showed that Black race, age greater than 60, and male gender were associated with positive COVID-19 tests in a study of 2,595 patients. 17 In addition to race-based disparities in COVID-19 outcomes, cancer continues to be a negative risk factor for outcomes in COVID-19 patients. Specifically, Al-Shamsi et al showed that compared to the general population, cancer patients not only had a significantly higher rate of coronavirus (29.4% vs.0.5%), but also that these patients were significantly more likely to be hospitalized (28.1% vs 10.4%). 18 Furthermore, Pinato et al showed European cancer patients with COVID-19 had a 33% mortality rate and that male gender, age greater than 65, and the presence of less than two comorbidities prior to infection were significantly associated with the development of a complication from COVID-19. 19 Our study found limited utility with regard to generalized COVID-19 testing of radiation oncology patients despite the high incidence of cases in the area. Our study is in agreement with prior studies which found low positivity rates in asymptomatic cancer patients, including the aforementioned study from Germany, which found a positivity rate of less than 1%. 10 . Additionally, in a recent study by Jan et al, which was performed at one of the institutions included in the current study during the same timeperiod, multiple-surfaces were tested for SARS-COV-2 in a radiation oncology clinic, but zero positive samples were collected, thereby, indicating the safety of radiation oncology clinics and the importance of treating without delay 20 .

While the strength of our study is that it is the only study detailing the results of asymptomatic testing in radiation oncology patients in the United States, it also has limitations. First, given that each institution had varying methods for determining risk and the need for COVID testing, our study may be limited by sampling bias. Nevertheless, the demographics of our patient population as seen in Tables 1 and 2 demonstrate that we have a representative sample of the radiation oncology population. Second, our study is limited by the fact that only a small percentage of patients tested positive, resulting in large 95% confidence intervals and limited statistical comparisons. However, the fraction of asymptomatic patients was hypothesized to be small, and the statistically significant findings in this study do warrant further consideration.

In summary, our study sought to determine the prevalence of asymptomatic COVID-19 rates in cancer patients. We found a low pre-treatment prevalance of 1.3%, thereby suggesting that broadbased pre-treatment asymptomatic testing of radiation oncology patients for SARS-COV-2 is of limited value even in the setting of high community prevalence. Should there be another wave of infections, this study may help with implementing testing in asymptomatic patients, ultimately leading to a decrease in asymptomatic transmission and a reduction in disruptions in care. While current measures to mitigate risk such as the use of masks, social distancing, and hand hygiene are important, future strategies should focus on targeted asymptomatic testing for high-risk patients, including those with advanced stage, active chemotherapy, and underserved populations. 

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

COVID-19 Clinical Guidance

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19

CDC. Pandemic Planning Scenarios

Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and metaanalysis

Temporal dynamics in viral shedding and transmissibility of COVID-19

Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts

Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset

SARS-CoV-2 prevalence in an asymptomatic cancer cohort -results and consequences for clinical routine

Screening for COVID-19 in Asymptomatic Patients With Cancer in a Hospital in the United Arab Emirates

Utility of COVID-19 Screening in Cancer Patients

Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children

Assessment of Disparities in COVID-19 Testing and Infection Across Language Groups in

Racial Disparities in Incidence and Outcomes Among Patients With COVID-19

Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

Prevalence of Surface Contamination With SARS-CoV-2 in a Radiation Oncology Clinic